Gilead Sciences (NASDAQ:GILD) had its price target dropped by research analysts at Leerink Swann from $86.00 to $83.00 in a research note issued on Wednesday. The brokerage currently has a “market perform” rating on the biopharmaceutical company’s stock. Leerink Swann’s price objective points to a potential upside of 6.11% from the company’s previous close.

GILD has been the topic of a number of other research reports. Credit Suisse Group set a $80.00 target price on Gilead Sciences and gave the company a “hold” rating in a report on Wednesday, January 3rd. Mizuho raised their target price on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. BMO Capital Markets reduced their target price on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a report on Friday, October 27th. BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a report on Thursday, December 14th. Finally, Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a report on Thursday, January 18th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and an average target price of $86.56.

Gilead Sciences (GILD) opened at $78.22 on Wednesday. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $89.54. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. The company has a market capitalization of $102,150.00, a price-to-earnings ratio of 22.48, a price-to-earnings-growth ratio of -1.77 and a beta of 1.22.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the Zacks’ consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion for the quarter, compared to analyst estimates of $5.71 billion. Gilead Sciences had a return on equity of 48.88% and a net margin of 17.73%. The company’s revenue was down 18.7% on a year-over-year basis. During the same quarter last year, the company earned $2.70 EPS. equities analysts forecast that Gilead Sciences will post 6.47 earnings per share for the current year.

In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of Gilead Sciences stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total value of $3,681,000.00. Following the transaction, the insider now directly owns 3,046,766 shares in the company, valued at $224,302,912.92. The disclosure for this sale can be found here. Insiders have sold a total of 578,333 shares of company stock worth $44,100,508 over the last ninety days. Company insiders own 1.30% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in GILD. Welch Investments LLC acquired a new position in Gilead Sciences during the 3rd quarter worth about $108,000. Wealthcare Advisory Partners LLC bought a new position in shares of Gilead Sciences in the 3rd quarter worth about $133,000. Horan Capital Advisors LLC. bought a new position in shares of Gilead Sciences in the 3rd quarter worth about $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Gilead Sciences in the 2nd quarter worth about $147,000. Finally, Hanson & Doremus Investment Management raised its position in shares of Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares in the last quarter. 75.84% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This report was originally reported by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.dailypolitical.com/2018/02/09/leerink-swann-lowers-gilead-sciences-gild-price-target-to-83-00.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.